Eli Lilly and Company (NYSE:LLY) Shares Purchased by Bourne Lent Asset Management Inc.

Bourne Lent Asset Management Inc. raised its position in Eli Lilly and Company (NYSE:LLY) by 0.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,907 shares of the company’s stock after purchasing an additional 19 shares during the quarter. Eli Lilly and Company comprises 1.3% of Bourne Lent Asset Management Inc.’s investment portfolio, making the stock its 14th biggest position. Bourne Lent Asset Management Inc.’s holdings in Eli Lilly and Company were worth $3,461,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Kapitalo Investimentos Ltda purchased a new position in shares of Eli Lilly and Company during the 4th quarter worth $305,000. Orrstown Financial Services Inc. lifted its holdings in shares of Eli Lilly and Company by 2.6% in the 1st quarter. Orrstown Financial Services Inc. now owns 824 shares of the company’s stock worth $641,000 after acquiring an additional 21 shares during the last quarter. Advance Capital Management Inc. acquired a new stake in Eli Lilly and Company in the 1st quarter valued at approximately $223,000. Moseley Investment Management Inc. raised its position in Eli Lilly and Company by 0.4% in the first quarter. Moseley Investment Management Inc. now owns 3,890 shares of the company’s stock valued at $3,027,000 after purchasing an additional 14 shares during the period. Finally, CWM LLC boosted its position in shares of Eli Lilly and Company by 7.9% during the first quarter. CWM LLC now owns 68,862 shares of the company’s stock worth $53,572,000 after buying an additional 5,041 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 1.7 %

LLY opened at $913.85 on Wednesday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53. The stock has a market capitalization of $868.53 billion, a P/E ratio of 134.59, a P/E/G ratio of 2.79 and a beta of 0.42. The business has a 50 day simple moving average of $916.37 and a 200-day simple moving average of $855.42.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. On average, equities analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on LLY. Barclays increased their price target on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Jefferies Financial Group increased their price objective on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research note on Monday, June 24th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $1,025.00 price target on shares of Eli Lilly and Company in a report on Thursday, October 3rd. Finally, BMO Capital Markets lifted their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $979.29.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.